I suspect that the cases where Phase II trials are ended prematurely because the results are "too good" are most likely to be cases where the placebo patients are likely to face death or serious consequences; not saying that these genetic conditions aren't serious, but the placebo condition corresponds to "things the same as they were" not "things getting much much worse".
Don't take this as a put down, but we've actually learned no new information here. We know that they aim to finish during H12014. We know they aim to fast track. We know the situation with dosing and timespans from the clinicaltrials site. (Though the reason why they jumped from 28 to 14 and back again is a bit of a mystery- trying to keep costs down? Starting consedrvative and then amping up?)
Anyway the next big event in the 2566 space (for me) will be the Fragile-X trials kicking into gear (hopefully October-November). And hopefully the Perseis results will be on time or close to it.
NEU Price at posting:
9.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)